断藤益母汤治疗类风湿关节炎的临床及实验研究
|
摘要
目的
本研究分为两部分：临床部分通过采取随机、阳性平行对照的试验设计,旨在观察、评价断藤益母汤治疗类风湿关节炎(RA)的临床疗效与安全性。实验部分是通过体外培养类风湿关节患者滑膜成纤维细胞原代细胞(RA-FLS),以含药血清为干预手段初步探讨断藤益母汤对RA-FLS异常增殖的抑制作用,同时探讨该药含药血清对RA-FLS中Toll样受体4(TLR4)人类髓样分化因子(MyD88)、核转录因子(NF-κ B)三个信号通路元件的影响,旨在从炎症信号转导通路及相关细胞因子的角度探索断藤益母汤这一昆明山海棠中药复方配伍抗RA的作用机制,为该药的临床应用提供理论和实验依据。
方法
一、临床部分
按1987年美国风湿病学学会(ACR) RA分类标准为诊断依据,共入选RA患者70例,简单数字随机化等分为两组：试验组：口服断藤益母汤(由川续断15g,益母草30g,桂林产昆明山海棠45g组成,其中昆明山海棠先煎3.5h,再加入其他两味药同煎0.5h)每日一剂,分早晚两次服用,每次150ml。对照组：口服来氟米特片20mg qd,(购自江苏新凯-长征制药公司)治疗,治疗12周。在治疗的第0、2、6、12周记录两组的观察指标,计算两组患者DAS28、 ACR20、 ACR50变化情况,评价疗效。主要观察指标包括：症状体征指标(压痛关节数、肿胀关节数、晨僵时间、患者及研究者病情总体情况VAS评分、疼痛VAS评分、HAQ评分)、炎症活动相关实验室指标(血沉、C反应蛋白、类风湿因子、血清TNF-α含量)、安全性观察指标：(血常规、肝功能、肾功能及女性患者月经情况及其他不良反应事件)。
二、体外细胞实验部分
1.制取含药血清清洁级环境中饲养12只清洁级健康雄性家兔,随机等分为3组按如下方法灌胃：西药组：来氟米特1.92mg·kg-1；中药组：3.45g·kg-1断藤益母草汤,对照组予等量生理盐水。给药一周后采血分离含药血清,冻存备用。
2.细胞培养和鉴定：组织块法体外培养原代RA-FLS细胞和正常FLS,光镜鉴定,实验用的RA-FLS3至5代处于对数生长期的细胞。细胞爬片苏木伊红染色作细胞形态学鉴定。免疫组化染色TLR4细胞爬片及滑膜组织切片。
3.各组RA-FLS抑制情况检测取RA-FLS,分成3组按以下方法干预：对照组(含10%对照组家兔血清的RPMI1640培养液),断藤益母汤组(含10%中药组家兔血清的RPMI1640培养液)和来氟米特组含10%西药组家兔血清的RPMI1640培养液)。分别常规培养24h、48h、72h后,用MTT法检测各组细胞的抑制率。
4. RT-PCR法检测各组细胞TLR4、MyD88的uRNA表达取RA-FLS,分组如下：.LPS组、.空白组、断藤益母汤组、来氟米特组。对照组(含10%对照组家兔血清的RPMI1640培养液),其余各组均加入LPS20μg· mL-1,含药血清干预方法同按MTT检测。培养24h后RT-PCR法检测TLR4、 MyD88mRNA表达。
5. ELISA法检测上一步处理后各组细胞培养上清中TNF-αa含量及细胞总蛋白中的核转录因子(NF-κ B)含量。
结果
一、临床部分
1.临床疗效评估共计64例患者(试验组33例、对照组31例)完成试验全程,6例因依从性不良退出。在治疗12周后,试验组ACR20, ACR50达标率分别为57.14%,20%；对照组ACR20、 ACR50达标率分别为62.86%,22.86%,此时两组间比较无明显差异(P>0.05)；按DAS28疗效评价,治疗12周后试验组总有效率为51.42%,对照组总有效率为57.14%,两组总有效率差异无明显统计意义(P>0.05)。较之基线水平,试验组在治疗2周、6周、12周ACR20达标例数均明显增多(P<0.01),在治疗6周、12周后ACR50达标例数均明显增多(P<0.01)；且该组治疗6周后ACR50达标例数高于2周后(P<0.05)；此外,治疗2周后试验组ACR20达标例数明显多于对照组(P<0.05),而对照组较基线水平明显起效是在6周以后(P<0.05)。
2.主要临床症状体征比较：试验组治疗2周后在压痛关节数、肿胀关节数、疼痛VAS评分、患者、研究者病情状况VAS评分、HAQ评分6方而较基线水平均有明显降低(P<0.05)。且此时试验组的肿胀关节数、HAQ评分、疼痛VAS评分、患者及研究者对病情状况VAS评分方面的改善程度明显优于对照组(P<0.05)；6周时试验组肿胀关节数、受试者对病情状况VAS评分明显低于对照组(P<0.05)。两组在所有7项指标在6周、12周后较基线均明显降低(P<0.05),治疗12周后,对照组在研究对患者者病情状况VAS评分、HAQ评分2项指标方面改善程度优于试验组(P<0.05)。两组在其余各项指标改善程度无明显差异(P>0.05)。
3.炎症活动相关指标两组风湿三项(血沉、C反应蛋白、类风湿因子)基线水平无明显差异(P>0.05),具备可比性。试验组在治疗2周后C反应蛋白水平较基线显著降低(P<0.05)；治疗6周、12周后,患者的风湿三项较基线水平进行性显著下降(P<0.05)；治疗2周后试验组C反应蛋白较对照组明显降低(P<0.05)；而对照组在治疗6周后、12周后风湿三项均较基线水平明显下降(P<0.05)；但治疗6、12周末两组的风湿三项数值无明显差异(P>0.05)。12周后,较各自基线水平两组TNF-α含量显著下降(P<0.01)但在0、12周两个时间点的组间比较均无明显差异(P>0.05)。
4.安全性指标两组中6个安全性指标(红细胞数、白细胞数、血红蛋白数、血肌酐、尿素氮、谷丙转氨酶、谷草转氨酶)在试验的4个时间点(0周,2周、6周、12周)中无明显差异,但12周末试验组在血小板数低于治疗前(P<0.05)。
5.不良反应试验组的35例患者中,服药后出现瘙痒皮疹的有1例,自行缓解；出现月经量变少3例,出现不良反应的患者均自愿坚持用药参加完实验全程；肾功能、血液分析未见明显异常。对照组的35例患者中,服药后10例出现轻度脱发,2例出现谷丙转氨酶一过性升高至正常2倍,加用护肝治疗2周后恢复正常,治疗过程中未停药,该组出现不良反应患者参加全程实验。
二、实验部分
1.成功建立RA-FLS细胞株,该细胞免疫组化染色示TLR4表达量较正常FLS增高。
2.MTT结果较之同一时点的对照组,在干预48h,72h后,中、西药含药血清均能抑制RA-FLS增殖,差异有显著统计意义(P<0.05),72h后,西药组细胞抑制程度明显强于中药组(P<0.05)。中、西药组细胞抑制率分别为25.7%、35.9%。
3.RT-PCR结果在干预24h后,LPS组细胞TLR4mRNA表达量明显高于对照组(P<0.05),相对于LPS组,而两种含药血清均可明显抑制TLR4mRNA表达量(P<0.05),但中药组、西药组、对照组3组的组间差异不具备显著统计意义(P>0.05)。各组间MyD88mRNA表达量含量无明显差异(P>0.05)。
4.ELISA检测结果干预24h后,LPS组与对照组细胞培养上清TNF-α含量相比较无显著差异(P>0.05)。较之LPS组,中药组细胞培养上清TNF-α含量明显降低(P<0.05)。LPS组总蛋白NF-κ B含量明显高于对照组(P<0.05),较之LPS组,两个含药血清组细胞总蛋白NF-κB含量均明显降低(P<0.05),来氟米特组NF-κ B含量明显低于对照组(P<0.05),中西药组间差异不明显(P>0.05)。
结论
1.经过12周治疗,断藤益母汤、来氟米特均均能有效减轻RA患者临床症状、降低炎症活动实验室指标和DAS28评分,在ACR20、 ACR50达标例数方面疗效相当。但断藤益母汤起效时间明显先于来氟米特,且能一定程度上降低血小板,可能与该方中益母草具有的抗血小板作用有关,但尚不能确定3例患者出现月经异常与服用该方相关。治疗前后两种药物在肝肾功、血常规方面无明显差异,无严重不良反应事件。
2.体外实验证明断藤益母汤、来氟米特含药血清能等效抑制RA-FLS的异常增殖,下调LPS刺激后RA-FLS中TLR4mRNA表达量和细胞总蛋白中的NF-κ B含量,断藤益母汤含药血清还能一定程度上降低LPS刺激引起RA-FLS分泌TNF-α,未见LPS刺激、含药血清对MyD88mRNA有调节作用,以上研究提示两种药物下调天然免疫蛋白TLR4和一定程度上影响下游信号元件NF-κ B合成是可能是它们抗RA作用机制之一,但尚不能确定这种机制是否同MyD88信号依赖性通路活化相关,具体途径尚待进一步研究。
Objective:
This subject include three parts. The first part is Literature Review, mainly introduced three aspects:illustrated the relation between pathogenesis of rheumatoid arthritis(RA) and Rheumatoid fibroblast-like synoiocytes (RA-FLS)activation, research summary about oral TCM therapy for RA, previous correlation study about Duanteng Yimu Decoction(DYD). The second part is a12-weeks trial to assess the efficacy and safety of DYD and Leflunomide for RA patients in active period. The third part is experiments to observe effects of DVD medicinal serum on RA-FLS and TLR4/NF-κ B signal transduction pathway, all above work is to provide to provide experimental and clinical basis for Using DYD to treat RA.
Methods
1. Clinical part:Accord RA classification criteria from American College of Rheumatology (ACR) Promulgated in1987for diagnosis,70RA cases were divided into test and control group according to the time sequence of seeing doctor.,35cases of test group, to DYD, a does one day,150ml Bid,35cases of control group,to LEF,20mg Qd.Observed clinical indexes of4time points (0w,2w,6w,12w) such as tender joint count,swollen joint count, morning stiffness duration,patient global assessment, overall pain VAS from patients and researcher, HAQ. Lab indexes of4time points (0w,2w,6w,12w) include RF, CRP, ESR. And serum TNF-α of2time points (0w,12w)is also measured and recorded. DAS28change, numbers of cases reached ACR20, ACR50were caculated according to above informations, index of security included routine blood test, renal (BUN,Cr), Liver function (ALT,AST).
2. Experimental parts:Synovial specimens obtained from the joint of patients were minced into small pieces of RA-FLS.The morphological features of RA-FLS subcultured for3-5generations were observed under inverted microscope.Our study was a two-stage procedure:evaluation of DYD effects on the the prolifration of RA-FLS at first, and then analysis of its effects on TLR4mRNA, MyD88mRNA,. NF-κ B of cells total protein, TNF-a from culture supernatants. In evaluation of DYD effects on RA-FLS, RA-FLS cells were divided into three groups:the control, LEFgroup(10%serum containing LEF) and DYD group(10%serum containing DYD) and then evaluated by MTT at three time points (24,48,72h). In evaluation of DYD effects on TLR4mRNA, MyD88mRNA. RA-FLS cells were divided into four groups:the control, model control(LPS20μg/ml), LEFgroup(LPS20μg/ml+10%serum containing LEF) and DYD groups(LPS20u g/ml+10%serum containingDYD), after24h, TLR4mRNA and MyD88mRNA of cells RNA from each groups were evaluated by RT-PCR, NF-κ B of cells total protein from each groups were evaluated by Elisa, TNF-α from culture supernatants of different groups were tested by Elisa.
Result
1. Clinical part:
(1)At last,31cases in control and33cases in test finished whole trail, cases shedded because of bad compliance.Accord to standard of DAS28, the total effective rate of test group is51.42%, this rate in the control is57.1%, no significant difference in total effective rate was found between the two groups (P>0.05). After treatments, DAS28, number of cases reach ACR20, ACR50in the two groups were improved obviously than12weeks before.(P<0.01).In test group, the rate reach ACR20is57.14%, the rate reach ACR50is20.00%, In the control group, the rate reach ACR20is62.86%, the rate reach ACR50is22.86%。 There is not significance between the rate reach ACR20, ACR50from the two groups (P>0.05).After12weeks, symptoms of patients from both groups were improved in tender joint number, swollen joint number, morning stiffness duration, patient global assessment, overall pain VAS from patients and researcher, HAQ.(P<0.01). At the end of2rd week, test group has obviously improved in the aforementioned aspects except morni ng stiffness (P<0.05), and compare to the control, the test group improved more significant in swollen and tender joint number, patient global assessment, overall pain VAS from patients and researcher, HAQ (P<0.05), until he end of6th week, in the aforementioned6aspects had been improved obviously in the control.(P<0.05),In the end, compare to the test group, overall pain VAS from patients and researcher, HAQ in the control group had been improved more obviously (P<0.05), no significant difference was found in any other Symptoms observation index.(P>0.05)
(2)Lab indexes:after treating for6wand12w, ESR,CRP and RF reduced significantly than baseline data in both groups (P<0.01), in the test group, CRP reduced significantly than baseline at the end of2rd week,(P <0.05) in the control, all the three indexes reduced obviously after6week (P<0.05).At the end of6and12week, TNF-α reduced obviously compare to baseline in both groups (P<0.01), but no difference between the two groups at the same time point (P>0.05)
(4) safety indexes:after12weeks, PLT in test group reduced compared to the baseline (P<0.05), no obvious difference was found in other indexes at any time point in the two groups (P>0.05)
(5) adverse reaction, lpatient got skin rash in the test group, but soon passed,3women had got few menstrual than before, but all of them adhere to the end. In the control,10patients lost their hair, there were2cases got AST increased to double than before, but released with treatments.
2. Experimental parts:
At the time point of48h,72h, compare to the control group, LEF and DYD serum have obviously inhibitive effects on the prolifration of RA-FLS from patients (P<0.05) Inhibition rate in LEF is higher than DYD groups after72h.(P <0.05), Similar efficacy is found in reduce of the expression of TLR4mRNA after intervene of LPS (P<0.05), but the effect has not a significant difference between the LEF and DYD group (P>0.05), expression of MyD88mRNA has not a significant difference between all the groups (P>0.05). Test result of TNF-α from control and LPS groups were not different particularly (P>0.05).while TNF-α in DYD group is less than LPS group (P<0.05). NF-κ B in LPS group is more than the control (P<0.05), compare to the control group, NF-κ B reduced more significantly in the two serum groups (P<0.05), LEF group is less than control group (P<0.05), no significant difference were found between LEF and DYD groups (P>0.05)
.Conclusion
1. after12weeks, DYD and LEF effectively improved clinical RA patients' symptoms, joint function and quality of life, reduced ESR, CRP, and RF, TNF-α in serum, but action of DYD occurs more faster than LEF. DYD reduced PLT partly may be explained as the leonurus in DYD has a effect of antiplatelet.Though3female patients in test group had got irregular menstruation, it remained to be seen in further clinical trail because climacterium may also result the same symptoms. While increasing levels of transaminases in LEF group were in agreement with references,No Serious adverse reaction happened in both groups meant the two drugs were safe withinl2weeks of treatment.
2. Serum contained DYD or LEF can inhibit RA-FLS proliferation in regular doses dose, and the does can reduce the expression of TLR4mRNA, NF-κB of cells total protein, but has no effects on expression of MyD88mRNA.The result suggested the therapeutic mechanism of DYD for RA may included two aspests, first DYD could restrain proliferation of RA-FLS, second DYD may downregulated the expression of components from TLR4/NF-κ B pathway, but it is not clear wether MyD88dependent pathway is activated be no association with MyD88.
本研究分为两部分：临床部分通过采取随机、阳性平行对照的试验设计,旨在观察、评价断藤益母汤治疗类风湿关节炎(RA)的临床疗效与安全性。实验部分是通过体外培养类风湿关节患者滑膜成纤维细胞原代细胞(RA-FLS),以含药血清为干预手段初步探讨断藤益母汤对RA-FLS异常增殖的抑制作用,同时探讨该药含药血清对RA-FLS中Toll样受体4(TLR4)人类髓样分化因子(MyD88)、核转录因子(NF-κ B)三个信号通路元件的影响,旨在从炎症信号转导通路及相关细胞因子的角度探索断藤益母汤这一昆明山海棠中药复方配伍抗RA的作用机制,为该药的临床应用提供理论和实验依据。
方法
一、临床部分
按1987年美国风湿病学学会(ACR) RA分类标准为诊断依据,共入选RA患者70例,简单数字随机化等分为两组：试验组：口服断藤益母汤(由川续断15g,益母草30g,桂林产昆明山海棠45g组成,其中昆明山海棠先煎3.5h,再加入其他两味药同煎0.5h)每日一剂,分早晚两次服用,每次150ml。对照组：口服来氟米特片20mg qd,(购自江苏新凯-长征制药公司)治疗,治疗12周。在治疗的第0、2、6、12周记录两组的观察指标,计算两组患者DAS28、 ACR20、 ACR50变化情况,评价疗效。主要观察指标包括：症状体征指标(压痛关节数、肿胀关节数、晨僵时间、患者及研究者病情总体情况VAS评分、疼痛VAS评分、HAQ评分)、炎症活动相关实验室指标(血沉、C反应蛋白、类风湿因子、血清TNF-α含量)、安全性观察指标：(血常规、肝功能、肾功能及女性患者月经情况及其他不良反应事件)。
二、体外细胞实验部分
1.制取含药血清清洁级环境中饲养12只清洁级健康雄性家兔,随机等分为3组按如下方法灌胃：西药组：来氟米特1.92mg·kg-1；中药组：3.45g·kg-1断藤益母草汤,对照组予等量生理盐水。给药一周后采血分离含药血清,冻存备用。
2.细胞培养和鉴定：组织块法体外培养原代RA-FLS细胞和正常FLS,光镜鉴定,实验用的RA-FLS3至5代处于对数生长期的细胞。细胞爬片苏木伊红染色作细胞形态学鉴定。免疫组化染色TLR4细胞爬片及滑膜组织切片。
3.各组RA-FLS抑制情况检测取RA-FLS,分成3组按以下方法干预：对照组(含10%对照组家兔血清的RPMI1640培养液),断藤益母汤组(含10%中药组家兔血清的RPMI1640培养液)和来氟米特组含10%西药组家兔血清的RPMI1640培养液)。分别常规培养24h、48h、72h后,用MTT法检测各组细胞的抑制率。
4. RT-PCR法检测各组细胞TLR4、MyD88的uRNA表达取RA-FLS,分组如下：.LPS组、.空白组、断藤益母汤组、来氟米特组。对照组(含10%对照组家兔血清的RPMI1640培养液),其余各组均加入LPS20μg· mL-1,含药血清干预方法同按MTT检测。培养24h后RT-PCR法检测TLR4、 MyD88mRNA表达。
5. ELISA法检测上一步处理后各组细胞培养上清中TNF-αa含量及细胞总蛋白中的核转录因子(NF-κ B)含量。
结果
一、临床部分
1.临床疗效评估共计64例患者(试验组33例、对照组31例)完成试验全程,6例因依从性不良退出。在治疗12周后,试验组ACR20, ACR50达标率分别为57.14%,20%；对照组ACR20、 ACR50达标率分别为62.86%,22.86%,此时两组间比较无明显差异(P>0.05)；按DAS28疗效评价,治疗12周后试验组总有效率为51.42%,对照组总有效率为57.14%,两组总有效率差异无明显统计意义(P>0.05)。较之基线水平,试验组在治疗2周、6周、12周ACR20达标例数均明显增多(P<0.01),在治疗6周、12周后ACR50达标例数均明显增多(P<0.01)；且该组治疗6周后ACR50达标例数高于2周后(P<0.05)；此外,治疗2周后试验组ACR20达标例数明显多于对照组(P<0.05),而对照组较基线水平明显起效是在6周以后(P<0.05)。
2.主要临床症状体征比较：试验组治疗2周后在压痛关节数、肿胀关节数、疼痛VAS评分、患者、研究者病情状况VAS评分、HAQ评分6方而较基线水平均有明显降低(P<0.05)。且此时试验组的肿胀关节数、HAQ评分、疼痛VAS评分、患者及研究者对病情状况VAS评分方面的改善程度明显优于对照组(P<0.05)；6周时试验组肿胀关节数、受试者对病情状况VAS评分明显低于对照组(P<0.05)。两组在所有7项指标在6周、12周后较基线均明显降低(P<0.05),治疗12周后,对照组在研究对患者者病情状况VAS评分、HAQ评分2项指标方面改善程度优于试验组(P<0.05)。两组在其余各项指标改善程度无明显差异(P>0.05)。
3.炎症活动相关指标两组风湿三项(血沉、C反应蛋白、类风湿因子)基线水平无明显差异(P>0.05),具备可比性。试验组在治疗2周后C反应蛋白水平较基线显著降低(P<0.05)；治疗6周、12周后,患者的风湿三项较基线水平进行性显著下降(P<0.05)；治疗2周后试验组C反应蛋白较对照组明显降低(P<0.05)；而对照组在治疗6周后、12周后风湿三项均较基线水平明显下降(P<0.05)；但治疗6、12周末两组的风湿三项数值无明显差异(P>0.05)。12周后,较各自基线水平两组TNF-α含量显著下降(P<0.01)但在0、12周两个时间点的组间比较均无明显差异(P>0.05)。
4.安全性指标两组中6个安全性指标(红细胞数、白细胞数、血红蛋白数、血肌酐、尿素氮、谷丙转氨酶、谷草转氨酶)在试验的4个时间点(0周,2周、6周、12周)中无明显差异,但12周末试验组在血小板数低于治疗前(P<0.05)。
5.不良反应试验组的35例患者中,服药后出现瘙痒皮疹的有1例,自行缓解；出现月经量变少3例,出现不良反应的患者均自愿坚持用药参加完实验全程；肾功能、血液分析未见明显异常。对照组的35例患者中,服药后10例出现轻度脱发,2例出现谷丙转氨酶一过性升高至正常2倍,加用护肝治疗2周后恢复正常,治疗过程中未停药,该组出现不良反应患者参加全程实验。
二、实验部分
1.成功建立RA-FLS细胞株,该细胞免疫组化染色示TLR4表达量较正常FLS增高。
2.MTT结果较之同一时点的对照组,在干预48h,72h后,中、西药含药血清均能抑制RA-FLS增殖,差异有显著统计意义(P<0.05),72h后,西药组细胞抑制程度明显强于中药组(P<0.05)。中、西药组细胞抑制率分别为25.7%、35.9%。
3.RT-PCR结果在干预24h后,LPS组细胞TLR4mRNA表达量明显高于对照组(P<0.05),相对于LPS组,而两种含药血清均可明显抑制TLR4mRNA表达量(P<0.05),但中药组、西药组、对照组3组的组间差异不具备显著统计意义(P>0.05)。各组间MyD88mRNA表达量含量无明显差异(P>0.05)。
4.ELISA检测结果干预24h后,LPS组与对照组细胞培养上清TNF-α含量相比较无显著差异(P>0.05)。较之LPS组,中药组细胞培养上清TNF-α含量明显降低(P<0.05)。LPS组总蛋白NF-κ B含量明显高于对照组(P<0.05),较之LPS组,两个含药血清组细胞总蛋白NF-κB含量均明显降低(P<0.05),来氟米特组NF-κ B含量明显低于对照组(P<0.05),中西药组间差异不明显(P>0.05)。
结论
1.经过12周治疗,断藤益母汤、来氟米特均均能有效减轻RA患者临床症状、降低炎症活动实验室指标和DAS28评分,在ACR20、 ACR50达标例数方面疗效相当。但断藤益母汤起效时间明显先于来氟米特,且能一定程度上降低血小板,可能与该方中益母草具有的抗血小板作用有关,但尚不能确定3例患者出现月经异常与服用该方相关。治疗前后两种药物在肝肾功、血常规方面无明显差异,无严重不良反应事件。
2.体外实验证明断藤益母汤、来氟米特含药血清能等效抑制RA-FLS的异常增殖,下调LPS刺激后RA-FLS中TLR4mRNA表达量和细胞总蛋白中的NF-κ B含量,断藤益母汤含药血清还能一定程度上降低LPS刺激引起RA-FLS分泌TNF-α,未见LPS刺激、含药血清对MyD88mRNA有调节作用,以上研究提示两种药物下调天然免疫蛋白TLR4和一定程度上影响下游信号元件NF-κ B合成是可能是它们抗RA作用机制之一,但尚不能确定这种机制是否同MyD88信号依赖性通路活化相关,具体途径尚待进一步研究。
Objective:
This subject include three parts. The first part is Literature Review, mainly introduced three aspects:illustrated the relation between pathogenesis of rheumatoid arthritis(RA) and Rheumatoid fibroblast-like synoiocytes (RA-FLS)activation, research summary about oral TCM therapy for RA, previous correlation study about Duanteng Yimu Decoction(DYD). The second part is a12-weeks trial to assess the efficacy and safety of DYD and Leflunomide for RA patients in active period. The third part is experiments to observe effects of DVD medicinal serum on RA-FLS and TLR4/NF-κ B signal transduction pathway, all above work is to provide to provide experimental and clinical basis for Using DYD to treat RA.
Methods
1. Clinical part:Accord RA classification criteria from American College of Rheumatology (ACR) Promulgated in1987for diagnosis,70RA cases were divided into test and control group according to the time sequence of seeing doctor.,35cases of test group, to DYD, a does one day,150ml Bid,35cases of control group,to LEF,20mg Qd.Observed clinical indexes of4time points (0w,2w,6w,12w) such as tender joint count,swollen joint count, morning stiffness duration,patient global assessment, overall pain VAS from patients and researcher, HAQ. Lab indexes of4time points (0w,2w,6w,12w) include RF, CRP, ESR. And serum TNF-α of2time points (0w,12w)is also measured and recorded. DAS28change, numbers of cases reached ACR20, ACR50were caculated according to above informations, index of security included routine blood test, renal (BUN,Cr), Liver function (ALT,AST).
2. Experimental parts:Synovial specimens obtained from the joint of patients were minced into small pieces of RA-FLS.The morphological features of RA-FLS subcultured for3-5generations were observed under inverted microscope.Our study was a two-stage procedure:evaluation of DYD effects on the the prolifration of RA-FLS at first, and then analysis of its effects on TLR4mRNA, MyD88mRNA,. NF-κ B of cells total protein, TNF-a from culture supernatants. In evaluation of DYD effects on RA-FLS, RA-FLS cells were divided into three groups:the control, LEFgroup(10%serum containing LEF) and DYD group(10%serum containing DYD) and then evaluated by MTT at three time points (24,48,72h). In evaluation of DYD effects on TLR4mRNA, MyD88mRNA. RA-FLS cells were divided into four groups:the control, model control(LPS20μg/ml), LEFgroup(LPS20μg/ml+10%serum containing LEF) and DYD groups(LPS20u g/ml+10%serum containingDYD), after24h, TLR4mRNA and MyD88mRNA of cells RNA from each groups were evaluated by RT-PCR, NF-κ B of cells total protein from each groups were evaluated by Elisa, TNF-α from culture supernatants of different groups were tested by Elisa.
Result
1. Clinical part:
(1)At last,31cases in control and33cases in test finished whole trail, cases shedded because of bad compliance.Accord to standard of DAS28, the total effective rate of test group is51.42%, this rate in the control is57.1%, no significant difference in total effective rate was found between the two groups (P>0.05). After treatments, DAS28, number of cases reach ACR20, ACR50in the two groups were improved obviously than12weeks before.(P<0.01).In test group, the rate reach ACR20is57.14%, the rate reach ACR50is20.00%, In the control group, the rate reach ACR20is62.86%, the rate reach ACR50is22.86%。 There is not significance between the rate reach ACR20, ACR50from the two groups (P>0.05).After12weeks, symptoms of patients from both groups were improved in tender joint number, swollen joint number, morning stiffness duration, patient global assessment, overall pain VAS from patients and researcher, HAQ.(P<0.01). At the end of2rd week, test group has obviously improved in the aforementioned aspects except morni ng stiffness (P<0.05), and compare to the control, the test group improved more significant in swollen and tender joint number, patient global assessment, overall pain VAS from patients and researcher, HAQ (P<0.05), until he end of6th week, in the aforementioned6aspects had been improved obviously in the control.(P<0.05),In the end, compare to the test group, overall pain VAS from patients and researcher, HAQ in the control group had been improved more obviously (P<0.05), no significant difference was found in any other Symptoms observation index.(P>0.05)
(2)Lab indexes:after treating for6wand12w, ESR,CRP and RF reduced significantly than baseline data in both groups (P<0.01), in the test group, CRP reduced significantly than baseline at the end of2rd week,(P <0.05) in the control, all the three indexes reduced obviously after6week (P<0.05).At the end of6and12week, TNF-α reduced obviously compare to baseline in both groups (P<0.01), but no difference between the two groups at the same time point (P>0.05)
(4) safety indexes:after12weeks, PLT in test group reduced compared to the baseline (P<0.05), no obvious difference was found in other indexes at any time point in the two groups (P>0.05)
(5) adverse reaction, lpatient got skin rash in the test group, but soon passed,3women had got few menstrual than before, but all of them adhere to the end. In the control,10patients lost their hair, there were2cases got AST increased to double than before, but released with treatments.
2. Experimental parts:
At the time point of48h,72h, compare to the control group, LEF and DYD serum have obviously inhibitive effects on the prolifration of RA-FLS from patients (P<0.05) Inhibition rate in LEF is higher than DYD groups after72h.(P <0.05), Similar efficacy is found in reduce of the expression of TLR4mRNA after intervene of LPS (P<0.05), but the effect has not a significant difference between the LEF and DYD group (P>0.05), expression of MyD88mRNA has not a significant difference between all the groups (P>0.05). Test result of TNF-α from control and LPS groups were not different particularly (P>0.05).while TNF-α in DYD group is less than LPS group (P<0.05). NF-κ B in LPS group is more than the control (P<0.05), compare to the control group, NF-κ B reduced more significantly in the two serum groups (P<0.05), LEF group is less than control group (P<0.05), no significant difference were found between LEF and DYD groups (P>0.05)
.Conclusion
1. after12weeks, DYD and LEF effectively improved clinical RA patients' symptoms, joint function and quality of life, reduced ESR, CRP, and RF, TNF-α in serum, but action of DYD occurs more faster than LEF. DYD reduced PLT partly may be explained as the leonurus in DYD has a effect of antiplatelet.Though3female patients in test group had got irregular menstruation, it remained to be seen in further clinical trail because climacterium may also result the same symptoms. While increasing levels of transaminases in LEF group were in agreement with references,No Serious adverse reaction happened in both groups meant the two drugs were safe withinl2weeks of treatment.
2. Serum contained DYD or LEF can inhibit RA-FLS proliferation in regular doses dose, and the does can reduce the expression of TLR4mRNA, NF-κB of cells total protein, but has no effects on expression of MyD88mRNA.The result suggested the therapeutic mechanism of DYD for RA may included two aspests, first DYD could restrain proliferation of RA-FLS, second DYD may downregulated the expression of components from TLR4/NF-κ B pathway, but it is not clear wether MyD88dependent pathway is activated be no association with MyD88.
引文
[1]Connell L, Mcinnes IB. New cytokine target in inflammatory rheumatic diseases [J].Best Pract Res Clin Rheumatol,2006,20:865-878.
[2]L. C. Huber, O. Distler, I. Tarner, et al. Synovial fibroblasts:key players in rheumatoid arthritis [J]. Rheumatology,2006,45:669-675.
[3]KW Kim, ML Cho, SH Lee, et al. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation[J]. Immunology Letters.2007,110(1):54-64.
[4]Ishaq, M. Muhammad, JS. Hamed, et al. Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socioeconomic rheumatoid arthritis patients[J]. Modern Rheumatology. 2011,21(4):375-380.
[5]陈德超,三水白虎汤对滑膜成纤维细胞增殖和一氧化氮生成的抑制作用.博士论文.南方医科大学,47-56,2007.
[6]Juarez, M. Filer, A. Buckley, CD.Fibroblasts as therapeutic targets in rheumatoid arthritis and cancer. [N] Swiss Medical Weekly,2012,24(142):w13529.
[7]JK Ahn, JM Oh, Jj Lee, et al. Increased Extracellular Survivin in the Synovial Fluid of Rheumatoid Arthritis Patients:Fibroblast-like Synoviocytes as a Potential Source of Extracellular Survivin[Q]. Inflammation,2010,33(62):381-388.
[8]Komatsu, Noriko, Takayanagi, et al.Bone and cartilage destruction in rheumatoid arthritis[J]. Clinical calcium,2012,22(2):179-185.
[9]Weisbart Richard H, Chan Grace, Heinze Emil, et al. BRAF Drives Synovial Fibroblast Transformation in Rheumatoid Arthritis[J]. J Of Bio Chemistry,2010,285(45):34299-34303.
[10]王建光,类风湿滑膜成纤维细胞的比较蛋白质组学研究.博十论文.第二军医大学,7,2011,5.
[11]王磊,肖长虹.类风湿关节炎滑膜成纤维细胞增生的机制研究进展[C].全国第八届中西医结合风湿病学术会议论文汇编.北京.中国.2010.第1卷.
[12]David A. Schwartz, Donald N. Cook.Polymorphisms of the Toll-Like Receptors and Human Disease[J]. Clinical Infectious Diseases.2005,41(7):403-407.
[13]Stavros Garantziotis, John W. Hollingsworth, Aimee K. Zaas, et al.The Effect of Toll-Like Receptors and Toll-Like Receptor Genetics in Human Disease[J]. Annual Review of Medicine,2008,59:343-359.
[14]YC Lu, WC Yeh, Pamela S, et al. LPS/TLR4 signal transduction pathway [J]. Cytokine, 2008,42:145-151.
[15]陈洁,姜虹.TLR4信号通路与炎性反应[J].医学综述,2009,15(19)：2902-2904.
[16]张建军.TLR4受体及其信号通路在胰腺癌进展中的作用.博士论文.华中科技大学,8,2010.
[17]Ospelt C, Brentano F, Rengel Y. Overexpression of Toll-like Receptors 3 and 4 in Expression in Early and Longstanding Arthritis[J]. Arthritis AND Rheumatism, 2008, (58)12:3684-3692.
[18]Drexler Stefan K, Foxwell Brian M.The role of Toll-like receptors in chronic inflammation[J]. International Journal Of Biochemistry Cell Biology2009,(42)4:506-518.
[19]Diana L, Anderson. TNF:Inhibitors:A New Age in Rheumatoid Arthritis Treatment The American Journal of Nursing, 2004,104(2):60-69.
[20]涂巍,胡绍先.生物制剂治疗类风湿关节炎的应用策略[J].内科急危重症杂志,2010,(16)6：293-294.
[21]Shankar S, Handa R. Biological agents in rheumatoid arthritis[J]. J Postgrad Med, 2004,50(4):293-299.
[22]Shiro Ohshima, Yukihiko Saeki, Toru Mima. Interleukin 6 Plays a Key Role in the Development of Antigen-Induced Arthritis. Proceedings of the National Academy of Sciences of the United States of America. 1998(95)14:8222-8226.
[23]Song Soken-Nakazawa, Tomosugi Naohisa, Kawabata Hiroshi. IL-6 Plays an Essential Role in Multi-factors Associated Hepcidin Regulation:Anti-IL-6R Ab Therapy Improve Inflammatory Anemia in Multicentric Castleman's Disease (MCD) and Rheumatoid Arthritis (RA) Patients[J]. Clinical Immunology, 2010, 135(10):69-70.
[24]Nishimoto N, Hashimoto J, Miyasaka, N Blocking interleukin-6 (IL-6) by tocilizumab (A humanized anti-interleukin-6 receptor monoclonal antibody) monotherapy reduces joint damage in active rheumatoid arthritis (RA):Evidence from a X-ray reader-blinded randomised controlled trial[J]. Arithritis and Rheumatism,2005,52(12):4109.
[25]孙铁铮,吕厚山,药立波,等.类风湿关节炎与骨关节炎成纤维样滑膜细胞蛋白酪氨酸磷酸化状态的比较[J].中华骨科学杂志,2000,12：71-75.
[26]Migita K, Honda S, Yamasaki S, et al. Regulation of rheumatoid synovial cell grow th by ceramide[C].Bioch em Biophys Res Commun,2000,269(1):70-75.
[27]戴敏,魏伟.类风湿关节炎滑膜细胞信号转导机制研究进展[J].中国药理学通报,2003,19(5)：481-485.
[28]刘晓华,汤建平,郑肇巽,等.类风湿关节炎滑膜组织PDGF与TGF-β 1的表达与意义[J].山东医药,2002,42(18)：6-7.
[29]汤建平,刘晓华,郑肇巽.碱性成纤维细胞生长因子与转化生长因子β1在类风湿关节炎滑膜组织中的表达[J].江苏医药,2003,29(12)：893-894.
[30]刘宁涛,杨明辉,罗文丰,等.甲氨喋呤和雷公藤对类风湿关节炎滑膜细胞产生趋化因子的影响[J].第四军医大学学报,2006,27(12)：1113-1115.
[31]栗占国,张奉春,鲍春德.2008,类风湿关节炎[M].人民卫生出版社,46-47.
[32]司秀文,刘明,李梅.血管活性肠肽对类风湿关节炎作用的研究进展[J].细胞与分子免疫学杂志,2009,25(5)：473-475.
[33]Tang Y, Lv B, Wang H, et al. PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia[J]. Int Immuno pharmacol,2008,8(12): 1646-1651.
[34]许倬,管剑龙,韩星海.类风湿关节炎滑膜细胞周期的基因调节[J].中华风湿病学杂志,2002,6(2)：272-275.
[35]朱良春.益肾壮督治其本,虫蚁搜剔治其标[J].江苏中医药,2008,40(1)：2-3.
[36]王振亮.肝与类风湿关节炎的关系及从肝论治[J].中医研究,2008,21(11)：49-51.
[37]林昌松,关彤,刘晓玲,等.陈纪藩治疗类风湿关节炎临证经验述要[J].中医药学刊,2004,22(2)：214-216.
[38]侯俊峰.《金匮要略》痹证论治探析[J].甘肃中医,2003,16(3)：3-4.
[39]娄玉钤.风湿病“虚、邪、瘀”理论浅析[J].中医杂志,2008,49(7)：669.
[40]吴佩田.如何辨治类风湿关节炎[J].中医杂志,2007,48(6)：567-568.
[41]赵孝怀.类风湿关节炎的诊治心得[J].辽宁中医杂志,2003,30(5)：369.
[42]李景辉.莫成荣治疗类风湿关节炎经验[J].辽宁中医杂志,2004,31(1)：5-6.
[43]马宝东.辩证治疗类风湿关节炎分析[J].实用中医内科杂志,2007,21(7)：31.
[44]王义军.关于中医药阻止类风湿关节炎骨侵蚀的儿点思考[J].中国中医风湿病杂志,2010,13(3)：282-283.
[45]秦林,滕佳林,叶蕾,等.类风湿关节炎从肝脾辨证的研究概况[J].上海中医药杂志,2006,40(3)：65-67.
[46]高明利.从中医体质学说辨析类风湿关节炎[D].辽宁：辽宁中医药大学,2008.
[47]张之澧.雷公藤颗粒冲剂治疗类风湿关节炎及强直性脊柱炎的临床观察[J].上海中医药杂志,1988,(11)：30.
[48]涂胜豪,胡永红.雷公藤片治疗类风湿关节炎的疗效和生活质量评价[J].湖南中医学院学报,2006,26(2)：25-27.
[49]王轶,吴强,魏佳熙,等.帕夫林、MIX及雷公藤对RA临床指标影响的观察[J].中国老年保健医学,2005,3(4)：51-53.
[50]Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis:A randomized trial [J]. Annals of Internal Medicine,2009,151(4):229-240.
[51]陈鹏,朱琳,周荥,等.雷公藤多苷联合甲氨蝶呤治疗类风湿关节炎的随机对照试验[J].安徽中医学院学报,2011,30(6)：28-34.
[52]胡永红,翁庚民,陆付耳,等.雷公藤甲素诱导胶原诱导的关节炎大鼠滑膜细胞凋亡的初步观察[J].中华风湿病学杂志,2004,8(3)：131.
[53]范仰钢,李国华.昆明山海棠联合甲氨蝶呤治疗老年起病类风湿关节炎[J].现代医药卫生,2006,22(4)：478-480.
[54]王浴生,邓文龙,薛春生.中药药理与应用[M].北京：人民卫生出版社,1999,2：688-696.
[55]吴湘慧,李娟,庞捷.类风湿关节炎大鼠模型的构建及昆明山海棠对大鼠佐剂性关节炎的干预研究[J].中药材,2009,32(5)：758-760.
[56]王有志,李春荣,莫志贤.青风藤化学成分与药理研究进展[J].医药导报,2004,23(3)：177-182.
[57]林小军,蔡小燕,叶静华.青藤碱治疗类风湿关节炎临床观察[J].湖南中医药大学学报,2009,29(8)：52-55.
[58]韩春雯,李海昌,汪梅姣.正清风痛宁治疗类风湿关节炎文献研究[J].吉林中医药,2012,32(2)：161-164.
[59]缪建春,蔡威黔.天然药物抗类风湿关节炎作用的研究进展[J].医药导报,2010,29(7)：872-875.
[60]闵伟,琪魏琴,李洪毓,等.白芍总苷治疗类风湿关节炎的多中心临床研究[J].中华风湿病学杂志,2005,9(8)：487-492.
[61]尹耕,谢其冰.白芍总苷治疗类风湿关节炎60例临床分析[J].现代预防医学,2007,34(9)：3791-3794.
[62]张源潮,杨清锐,尹宏恩,等.草乌甲素治疗骨关节炎及类风湿关节炎临床观察[J].中药药理与临床2000,16(2)：43-45.
[63]Yin W, Wang Ts, Yin FZ, et al. Analgesic and anti-inflammatory properities of brucine and brucine Noxide extracted from seeds of Strychnos mix vomica[J]. J Ethnopharmacol.2003, 88 (2-3):205-214.
[64]马强,陈刚,张继芬,等.川芎嗪调控血管内皮生长因子与抗大鼠佐剂性关节炎的相关性研究[J].中国中药杂志,2009,34(21)：2799-2802.
[65]陈尹,魏伟,吴虹,等.木瓜苷对佐剂性关节炎大鼠血清抗体水平的下调作用[J].中国药理学通报,2007,23(7)：941-944.
[66]唐玲丽,高洁生,陈新瑞,等.白藜芦醇体外抑制类风湿关节炎滑膜细胞的增殖及其机制[J].中南大学学报(医学版),2006,31(4)：528-534.
[67]崔向军,王燕燕,侯晓强,等.青蒿琥酯治疗类风湿关节炎的临床观察[J].中国医院药学杂志,2007,27(5)：645-646.
[68]郭会卿.益肾蠲痹丸治疗顽痹150例疗效观察[J].时珍国医国药,2006,17(10)：2039-2040.
[69]张波,张继平,周少雄.益肾蠲痹丸对类风湿患者抗CCP抗体及AKA抗体的影响[J].广东医学,2009,30(1)：137-140.
[70]卢毓雄,于哗,王珏,等.益肾蠲痹丸与布洛芬治疗佐剂性关节炎大鼠模型的实验研究[J].中国中医基础医学杂志,2006,12(7)：2039-2040.
[71]简任佑.类风湿关节炎辨证初步研究及通痹灵治疗类风湿关节炎疗效观察,博士论文.广州中医药大学,9,2005.
[72]陈光星.中医药治疗类风湿关节炎的作用环节与细胞免疫调控机理研究,博士论文.广州中医药大学,31,2005.
[73]陈纪藩,赵会芳,沈晓燕,等.通痹灵对佐剂性关节炎大鼠滑膜细胞产生IL-1、 TNF-α、 PGE2的影响[J].广州中医药大学学报,1999,16(1)：30-33.
[74]黄清春,储永良,接力刚,等.通痹灵对类风湿关节炎滑膜血管内皮生长因子mRNA的影响[J].中国中医药信息杂志,2009,16(2)：34-40.
[75]林昌松,王笑丹,徐强,等.昆仙胶囊联合甲氨蝶呤治疗类风湿关节炎疗效观察[J].陕西中医,2010,31(8)：987-992.
[76]王笑丹.昆仙胶囊治疗类风湿关节炎临床疗效评价及对CIA大鼠IL-8、 γIP10的影响博十论文.广州中医药大学,2,2010.
[77]关彤,林昌松,陈光星,等.二藤通痹合剂治疗类风湿关节炎60例临床观察[J].中国中医 急症,2009,18(11)：1792-1795.
[78]徐强,林昌松,刘清平,等.通痹合剂2号治疗类风湿关节炎的临床观察[J].辽宁中医杂志,2010,37(9)：1763-1766.
[79]陈辉,陈纪藩,黄胜光,等.通痹合剂对雄性大鼠生殖器官的毒性影响[J].中华中医药学刊,2010,28(11)：2432-2434.
[80]余晓芬.断藤蝎子汤治疗类风湿关节炎的临床观察,硕十论文.广州中医药大学,45,2009.
[81]姜晓,敖林,崔志鸿,等.昆明山海棠总生物碱对LPS诱导的小鼠RAW264.7细胞分泌TNF-αNO的影响[J].中医药导报,2011,17(3)：82-84.
[82]万屏,王红兵,吕昭萍,等.昆明山海棠对血管内皮细胞ICAM-1表达的影响[J].中国皮肤性病学,2001,15(4)：238-239.
[83]张航行,耿会玲,杨维霞.昆明山海棠的化学成分及药理活性研究进展[J].动物医学进展,2002,6(23)：42-45.
[84]王兆铭.中国中西医结合治疗风湿病学[M].北京：中医占籍出版社,1997,2：468-469.
[85]汤勇,展鸿谋.昆明山海棠的免疫抑制机理研究进展[J].云南医药,2005,26(3)：289--291.
[86]昆明医学院微生物学教研组免疫组.昆明山海棠抑制抗体产生的初步实验,昆明医学院学报,1980(2)：1-2.
[87]林科雄,王长征,钱桂生.雷公藤甲索对诱导CD4、 CD8T细胞凋亡的影响[J].第三军大学学报,2000,22(2)：139-149.
[88]徐艳,万屏,何黎,等.昆明山海棠片对小鼠淋巴细胞体外增殖活化影响的研究[J].中药材,2008,31(4)：557-561.
[89]李晟,徐开林,李振宇,等.昆明山海棠提取物对异基因骨髓移植小鼠调节性T细胞的影响[J].中国中西医结合杂志,2009,29(10)：910-914.
[90]周江桥,陈晖,陈志远,等.雷公藤内酯醇对大鼠肾缺血再灌注损伤时Toll样受体4表达的影响[J].中华器官移植杂志,2010,31(11)：688-693.
[91]黄晓春,周燕虹,杨录军,等.昆明山海棠总生物碱体外抗肿瘤作用的研究[J].中国医药学杂志,2006,26(4)：442-445.
[92]白玲,陈森洲,梁爽,等.昆明山海棠对CIA大鼠模型中HIF-1α表达的影响[J].细胞与分子免疫学杂志,2011,27(10)：1061-1064
[93]刘剑毅,罗先饮,黄思行.昆明山海棠片对大鼠睾丸功能标志酶活性的影响[C].首届中国药物毒理学年会,上海,2011.
[94]徐成康,赵云荷.昆明山海棠对育龄期妇女卵巢功能的影响[J].中山大学学报(医学科学版),2008,29(2)：202-205.
[95]钟美英,申玉华.川续断的研究现状[J].中医药导报,2008,14(6)：137-139.
[96]高秀芝,马鲁豫,金艳霞,等.川续断化学成分及药理作用研究进展[J].亚太传统医药学,2010,6(7)：142-146.
[97]刘二伟,吴帅,樊官伟.川续断的化学成分及药理作用进展[J].中华中医药学刊,2010,28(7)：1421-1423.
[98]张琪,汪仙阳,马博,等.复方续断总皂苷镇痛抗炎及预防骨质疏松症的实验研究[J].时珍国医药,2010,21(7)：1683-1684.
[99]刘浩,刘清平,陈纪藩,等.通痹合剂2号对胶原诱导型关节炎大鼠外周血CD28和CD152表 达以及肿瘤坏死因子-α含量的影响[J].中西医结合报,2008,6(7)：744-747.
[100]肖培根.新编中药志[M].北京：化学工业出版社,2002,3：269-270.
[101]刘圣君,任君旭,刘艳凯.益母草对失血性休克大鼠血流动力学的影响[J].中国临床康复,2006,23(10)：70.
[102]刘艳凯,魏会平,杜舒婷,等.益母草注射液对失血性休克大鼠转归时淋巴循环的干预作用[J].中国微循环,2006,10(5)：349.
[104]刘建平.随机对照的依从性和意向性治疗分析[J].中国中西医结合杂志,2003,23(12)：884-886.
[104]Moreland LW. Potential biologic agents for treating rheumatoid arthritis[J]. Rheumatic Diseases Clinics of North Anlerica,2001,27:445-491.
[105]曾润铭,杜世新,吴杰,等.昆明山海棠与类风湿关节炎滑膜细胞体外增殖和凋亡[J].中国组织工程研究与临床康复,2009,13(50)：9892-9896.
[106]王建竹,连金饶,孔祥英,等.雷公藤甲素对TNF-a诱导的滑膜细胞增殖的影响及对Ras-MAPKs信号转导通路的调控作用[J].中国中医药杂志,2010,35(7)：888-891.
[107]周江桥,陈晖,陈志远,等.雷公藤内酯醇对大鼠肾缺血再灌注损伤时Toll样受体4表达的影响[J].中华器官移植杂志,2010,31(11)：688-691.
[108]吴帅,刘虹,刘二伟,等.川续断属植物化学成分的研究概况[J].中华中医药学刊,2009,27(12)：2504-2507.
[109]冀红,侯晓明,廖磊.复方益母草膏药效学实验研究[J].首都医药,2006,8(4)：41-43.
[110]黄建林,巫世瑶,古洁若,等.来氟米特治疗类风湿关节炎的上市后安全性再观察[J].广东医学,2010,31(14)：1870-1872.
[111]王艳娇,李琳芸,彭长华,等.类风湿关节炎患者血清炎性因子、ANCA水平与血管内皮损伤标志物的相关性分析[J].循环学杂志,2012,22(1)：49-51.
[112]王宏伟,类风湿关节炎患者血清肿瘤坏死因子α的水平测定与临床意义[J].甘肃中医学院学报,2011,(28)6：51-52.
[113]李振彬,杨志霞,徐铮,等.活动期类风湿关节炎患者血清MMF,TNF-α,IL-1β表达的相关性研究[J].中国临床医学,2008,(15)4：558-561.
[114]Zvaifler NJ, Tsai V, Alsalamch S, et al. Pannocytes:distinetive cells found in rheumatoid arthritis articular cartilage erosions[J]. Am J Pathol 1997:150(3):1125-1138.
[115]Goto M, Sasano M, Yamanaka H, et al Spontaneous production of an interleukin IL-1 like factor by cloned Rheumatoid synovial cell in long-term culture[J]. Clin Invest,1987, 80 (3):786-796.
[116]Grabaek PM. Ultrastructural evidence for two distinct types of synoviocytes in rat synovial membrane [J]. J Ultrastruct Res, 1982, 78(3):321-339
[117]姚琦,袁丁.类风湿关节炎滑膜细胞凋亡研究进展[J].陕西医学杂志,2006(35)7：862-864.
[118]孟列素,朱文华,吕社民.Toll样受体与类风湿关节炎[J].中华风湿病学杂志,2008,1(1)：45-48.
[119]Lories RJ, Derease I, De Bari C, et al. In vitro growth rate of fibroblast-like synovial cells is reduced by methotrexate treated. Ann Rheum Dis 2003:62(6):568-71.
[120]刘巧红,沈凌汛,滕云,等.甲氨蝶呤对类风湿关节炎滑膜细胞增生及细胞周期的影响[J].中华风湿病学杂志,2004,8(4)：223-226
[121]杨志霞,李振彬,罗秋华,等雷公藤甲索含药血清对大鼠成纤维样滑膜细胞增殖及其巨噬细胞移动抑制因子表达的影响[J].中国组织工程研究与临床康复.2007,(11)49：9882-9885.
[122]叶永安,朱陵群.中药复方血清药理学方法在中医药研究中应用的思考[J].中国中医基础医学杂志,2001,(7)5：323-324.
[123]赵保胜,李兰芳,马悦颖,等.参苏饮含药血清对小鼠巨噬细胞Toll样受体及其下游信号转导通路的影响[J].中国中药杂志,2007,32(4)：327-331.
[124]LiLiu, Yu H. Li, Yin, B. Niu, et al. An apple oligogalactan prevents against inflammation and carcinogenesis by targeting LPS/TLR4/NF-KB pathway in a mouse model of colitis-associated colon cancer. [J]Carcinogenesis.2010, (31)10:1822-1832.
[125]朱熠,黄建鸣,张国楠TLR4/MyD88信号通路介导的卵巢癌紫杉醇耐药机制的研究进展[J].中华妇产科杂志,2011,46(11)：873-875.
[126]张红鸭,康娟,韩文娟,等TLR4、 MyD88、 NF-KB mRNA在实验性自身免疫性肌炎小鼠淋巴结中的表达和意义[J].细胞与分子免疫学杂志,2012,28(3)：272-276.
[127]熊小泉,石文,黄宪章.TLR4介导的固有免疫在类风湿关节炎模型大鼠中的发病过程中的意义[J].广东医学,2009,30(10)：1471-1473.
[128]Leah Emma. Rheumatoid arthritis:Spontaneous release of cytokines from synovial tissue is blocked by anti-TLR2[J].Nature Reviews Rheumatology.2011, (7)5:254.
[129]Jin Juan, Chan Yan, Wei Wei, Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis[J]. Acta Pharmacologica Sinica.2010, (31)9:1133-1140.
[2]L. C. Huber, O. Distler, I. Tarner, et al. Synovial fibroblasts:key players in rheumatoid arthritis [J]. Rheumatology,2006,45:669-675.
[3]KW Kim, ML Cho, SH Lee, et al. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation[J]. Immunology Letters.2007,110(1):54-64.
[4]Ishaq, M. Muhammad, JS. Hamed, et al. Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socioeconomic rheumatoid arthritis patients[J]. Modern Rheumatology. 2011,21(4):375-380.
[5]陈德超,三水白虎汤对滑膜成纤维细胞增殖和一氧化氮生成的抑制作用.博士论文.南方医科大学,47-56,2007.
[6]Juarez, M. Filer, A. Buckley, CD.Fibroblasts as therapeutic targets in rheumatoid arthritis and cancer. [N] Swiss Medical Weekly,2012,24(142):w13529.
[7]JK Ahn, JM Oh, Jj Lee, et al. Increased Extracellular Survivin in the Synovial Fluid of Rheumatoid Arthritis Patients:Fibroblast-like Synoviocytes as a Potential Source of Extracellular Survivin[Q]. Inflammation,2010,33(62):381-388.
[8]Komatsu, Noriko, Takayanagi, et al.Bone and cartilage destruction in rheumatoid arthritis[J]. Clinical calcium,2012,22(2):179-185.
[9]Weisbart Richard H, Chan Grace, Heinze Emil, et al. BRAF Drives Synovial Fibroblast Transformation in Rheumatoid Arthritis[J]. J Of Bio Chemistry,2010,285(45):34299-34303.
[10]王建光,类风湿滑膜成纤维细胞的比较蛋白质组学研究.博十论文.第二军医大学,7,2011,5.
[11]王磊,肖长虹.类风湿关节炎滑膜成纤维细胞增生的机制研究进展[C].全国第八届中西医结合风湿病学术会议论文汇编.北京.中国.2010.第1卷.
[12]David A. Schwartz, Donald N. Cook.Polymorphisms of the Toll-Like Receptors and Human Disease[J]. Clinical Infectious Diseases.2005,41(7):403-407.
[13]Stavros Garantziotis, John W. Hollingsworth, Aimee K. Zaas, et al.The Effect of Toll-Like Receptors and Toll-Like Receptor Genetics in Human Disease[J]. Annual Review of Medicine,2008,59:343-359.
[14]YC Lu, WC Yeh, Pamela S, et al. LPS/TLR4 signal transduction pathway [J]. Cytokine, 2008,42:145-151.
[15]陈洁,姜虹.TLR4信号通路与炎性反应[J].医学综述,2009,15(19)：2902-2904.
[16]张建军.TLR4受体及其信号通路在胰腺癌进展中的作用.博士论文.华中科技大学,8,2010.
[17]Ospelt C, Brentano F, Rengel Y. Overexpression of Toll-like Receptors 3 and 4 in Expression in Early and Longstanding Arthritis[J]. Arthritis AND Rheumatism, 2008, (58)12:3684-3692.
[18]Drexler Stefan K, Foxwell Brian M.The role of Toll-like receptors in chronic inflammation[J]. International Journal Of Biochemistry Cell Biology2009,(42)4:506-518.
[19]Diana L, Anderson. TNF:Inhibitors:A New Age in Rheumatoid Arthritis Treatment The American Journal of Nursing, 2004,104(2):60-69.
[20]涂巍,胡绍先.生物制剂治疗类风湿关节炎的应用策略[J].内科急危重症杂志,2010,(16)6：293-294.
[21]Shankar S, Handa R. Biological agents in rheumatoid arthritis[J]. J Postgrad Med, 2004,50(4):293-299.
[22]Shiro Ohshima, Yukihiko Saeki, Toru Mima. Interleukin 6 Plays a Key Role in the Development of Antigen-Induced Arthritis. Proceedings of the National Academy of Sciences of the United States of America. 1998(95)14:8222-8226.
[23]Song Soken-Nakazawa, Tomosugi Naohisa, Kawabata Hiroshi. IL-6 Plays an Essential Role in Multi-factors Associated Hepcidin Regulation:Anti-IL-6R Ab Therapy Improve Inflammatory Anemia in Multicentric Castleman's Disease (MCD) and Rheumatoid Arthritis (RA) Patients[J]. Clinical Immunology, 2010, 135(10):69-70.
[24]Nishimoto N, Hashimoto J, Miyasaka, N Blocking interleukin-6 (IL-6) by tocilizumab (A humanized anti-interleukin-6 receptor monoclonal antibody) monotherapy reduces joint damage in active rheumatoid arthritis (RA):Evidence from a X-ray reader-blinded randomised controlled trial[J]. Arithritis and Rheumatism,2005,52(12):4109.
[25]孙铁铮,吕厚山,药立波,等.类风湿关节炎与骨关节炎成纤维样滑膜细胞蛋白酪氨酸磷酸化状态的比较[J].中华骨科学杂志,2000,12：71-75.
[26]Migita K, Honda S, Yamasaki S, et al. Regulation of rheumatoid synovial cell grow th by ceramide[C].Bioch em Biophys Res Commun,2000,269(1):70-75.
[27]戴敏,魏伟.类风湿关节炎滑膜细胞信号转导机制研究进展[J].中国药理学通报,2003,19(5)：481-485.
[28]刘晓华,汤建平,郑肇巽,等.类风湿关节炎滑膜组织PDGF与TGF-β 1的表达与意义[J].山东医药,2002,42(18)：6-7.
[29]汤建平,刘晓华,郑肇巽.碱性成纤维细胞生长因子与转化生长因子β1在类风湿关节炎滑膜组织中的表达[J].江苏医药,2003,29(12)：893-894.
[30]刘宁涛,杨明辉,罗文丰,等.甲氨喋呤和雷公藤对类风湿关节炎滑膜细胞产生趋化因子的影响[J].第四军医大学学报,2006,27(12)：1113-1115.
[31]栗占国,张奉春,鲍春德.2008,类风湿关节炎[M].人民卫生出版社,46-47.
[32]司秀文,刘明,李梅.血管活性肠肽对类风湿关节炎作用的研究进展[J].细胞与分子免疫学杂志,2009,25(5)：473-475.
[33]Tang Y, Lv B, Wang H, et al. PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia[J]. Int Immuno pharmacol,2008,8(12): 1646-1651.
[34]许倬,管剑龙,韩星海.类风湿关节炎滑膜细胞周期的基因调节[J].中华风湿病学杂志,2002,6(2)：272-275.
[35]朱良春.益肾壮督治其本,虫蚁搜剔治其标[J].江苏中医药,2008,40(1)：2-3.
[36]王振亮.肝与类风湿关节炎的关系及从肝论治[J].中医研究,2008,21(11)：49-51.
[37]林昌松,关彤,刘晓玲,等.陈纪藩治疗类风湿关节炎临证经验述要[J].中医药学刊,2004,22(2)：214-216.
[38]侯俊峰.《金匮要略》痹证论治探析[J].甘肃中医,2003,16(3)：3-4.
[39]娄玉钤.风湿病“虚、邪、瘀”理论浅析[J].中医杂志,2008,49(7)：669.
[40]吴佩田.如何辨治类风湿关节炎[J].中医杂志,2007,48(6)：567-568.
[41]赵孝怀.类风湿关节炎的诊治心得[J].辽宁中医杂志,2003,30(5)：369.
[42]李景辉.莫成荣治疗类风湿关节炎经验[J].辽宁中医杂志,2004,31(1)：5-6.
[43]马宝东.辩证治疗类风湿关节炎分析[J].实用中医内科杂志,2007,21(7)：31.
[44]王义军.关于中医药阻止类风湿关节炎骨侵蚀的儿点思考[J].中国中医风湿病杂志,2010,13(3)：282-283.
[45]秦林,滕佳林,叶蕾,等.类风湿关节炎从肝脾辨证的研究概况[J].上海中医药杂志,2006,40(3)：65-67.
[46]高明利.从中医体质学说辨析类风湿关节炎[D].辽宁：辽宁中医药大学,2008.
[47]张之澧.雷公藤颗粒冲剂治疗类风湿关节炎及强直性脊柱炎的临床观察[J].上海中医药杂志,1988,(11)：30.
[48]涂胜豪,胡永红.雷公藤片治疗类风湿关节炎的疗效和生活质量评价[J].湖南中医学院学报,2006,26(2)：25-27.
[49]王轶,吴强,魏佳熙,等.帕夫林、MIX及雷公藤对RA临床指标影响的观察[J].中国老年保健医学,2005,3(4)：51-53.
[50]Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis:A randomized trial [J]. Annals of Internal Medicine,2009,151(4):229-240.
[51]陈鹏,朱琳,周荥,等.雷公藤多苷联合甲氨蝶呤治疗类风湿关节炎的随机对照试验[J].安徽中医学院学报,2011,30(6)：28-34.
[52]胡永红,翁庚民,陆付耳,等.雷公藤甲素诱导胶原诱导的关节炎大鼠滑膜细胞凋亡的初步观察[J].中华风湿病学杂志,2004,8(3)：131.
[53]范仰钢,李国华.昆明山海棠联合甲氨蝶呤治疗老年起病类风湿关节炎[J].现代医药卫生,2006,22(4)：478-480.
[54]王浴生,邓文龙,薛春生.中药药理与应用[M].北京：人民卫生出版社,1999,2：688-696.
[55]吴湘慧,李娟,庞捷.类风湿关节炎大鼠模型的构建及昆明山海棠对大鼠佐剂性关节炎的干预研究[J].中药材,2009,32(5)：758-760.
[56]王有志,李春荣,莫志贤.青风藤化学成分与药理研究进展[J].医药导报,2004,23(3)：177-182.
[57]林小军,蔡小燕,叶静华.青藤碱治疗类风湿关节炎临床观察[J].湖南中医药大学学报,2009,29(8)：52-55.
[58]韩春雯,李海昌,汪梅姣.正清风痛宁治疗类风湿关节炎文献研究[J].吉林中医药,2012,32(2)：161-164.
[59]缪建春,蔡威黔.天然药物抗类风湿关节炎作用的研究进展[J].医药导报,2010,29(7)：872-875.
[60]闵伟,琪魏琴,李洪毓,等.白芍总苷治疗类风湿关节炎的多中心临床研究[J].中华风湿病学杂志,2005,9(8)：487-492.
[61]尹耕,谢其冰.白芍总苷治疗类风湿关节炎60例临床分析[J].现代预防医学,2007,34(9)：3791-3794.
[62]张源潮,杨清锐,尹宏恩,等.草乌甲素治疗骨关节炎及类风湿关节炎临床观察[J].中药药理与临床2000,16(2)：43-45.
[63]Yin W, Wang Ts, Yin FZ, et al. Analgesic and anti-inflammatory properities of brucine and brucine Noxide extracted from seeds of Strychnos mix vomica[J]. J Ethnopharmacol.2003, 88 (2-3):205-214.
[64]马强,陈刚,张继芬,等.川芎嗪调控血管内皮生长因子与抗大鼠佐剂性关节炎的相关性研究[J].中国中药杂志,2009,34(21)：2799-2802.
[65]陈尹,魏伟,吴虹,等.木瓜苷对佐剂性关节炎大鼠血清抗体水平的下调作用[J].中国药理学通报,2007,23(7)：941-944.
[66]唐玲丽,高洁生,陈新瑞,等.白藜芦醇体外抑制类风湿关节炎滑膜细胞的增殖及其机制[J].中南大学学报(医学版),2006,31(4)：528-534.
[67]崔向军,王燕燕,侯晓强,等.青蒿琥酯治疗类风湿关节炎的临床观察[J].中国医院药学杂志,2007,27(5)：645-646.
[68]郭会卿.益肾蠲痹丸治疗顽痹150例疗效观察[J].时珍国医国药,2006,17(10)：2039-2040.
[69]张波,张继平,周少雄.益肾蠲痹丸对类风湿患者抗CCP抗体及AKA抗体的影响[J].广东医学,2009,30(1)：137-140.
[70]卢毓雄,于哗,王珏,等.益肾蠲痹丸与布洛芬治疗佐剂性关节炎大鼠模型的实验研究[J].中国中医基础医学杂志,2006,12(7)：2039-2040.
[71]简任佑.类风湿关节炎辨证初步研究及通痹灵治疗类风湿关节炎疗效观察,博士论文.广州中医药大学,9,2005.
[72]陈光星.中医药治疗类风湿关节炎的作用环节与细胞免疫调控机理研究,博士论文.广州中医药大学,31,2005.
[73]陈纪藩,赵会芳,沈晓燕,等.通痹灵对佐剂性关节炎大鼠滑膜细胞产生IL-1、 TNF-α、 PGE2的影响[J].广州中医药大学学报,1999,16(1)：30-33.
[74]黄清春,储永良,接力刚,等.通痹灵对类风湿关节炎滑膜血管内皮生长因子mRNA的影响[J].中国中医药信息杂志,2009,16(2)：34-40.
[75]林昌松,王笑丹,徐强,等.昆仙胶囊联合甲氨蝶呤治疗类风湿关节炎疗效观察[J].陕西中医,2010,31(8)：987-992.
[76]王笑丹.昆仙胶囊治疗类风湿关节炎临床疗效评价及对CIA大鼠IL-8、 γIP10的影响博十论文.广州中医药大学,2,2010.
[77]关彤,林昌松,陈光星,等.二藤通痹合剂治疗类风湿关节炎60例临床观察[J].中国中医 急症,2009,18(11)：1792-1795.
[78]徐强,林昌松,刘清平,等.通痹合剂2号治疗类风湿关节炎的临床观察[J].辽宁中医杂志,2010,37(9)：1763-1766.
[79]陈辉,陈纪藩,黄胜光,等.通痹合剂对雄性大鼠生殖器官的毒性影响[J].中华中医药学刊,2010,28(11)：2432-2434.
[80]余晓芬.断藤蝎子汤治疗类风湿关节炎的临床观察,硕十论文.广州中医药大学,45,2009.
[81]姜晓,敖林,崔志鸿,等.昆明山海棠总生物碱对LPS诱导的小鼠RAW264.7细胞分泌TNF-αNO的影响[J].中医药导报,2011,17(3)：82-84.
[82]万屏,王红兵,吕昭萍,等.昆明山海棠对血管内皮细胞ICAM-1表达的影响[J].中国皮肤性病学,2001,15(4)：238-239.
[83]张航行,耿会玲,杨维霞.昆明山海棠的化学成分及药理活性研究进展[J].动物医学进展,2002,6(23)：42-45.
[84]王兆铭.中国中西医结合治疗风湿病学[M].北京：中医占籍出版社,1997,2：468-469.
[85]汤勇,展鸿谋.昆明山海棠的免疫抑制机理研究进展[J].云南医药,2005,26(3)：289--291.
[86]昆明医学院微生物学教研组免疫组.昆明山海棠抑制抗体产生的初步实验,昆明医学院学报,1980(2)：1-2.
[87]林科雄,王长征,钱桂生.雷公藤甲索对诱导CD4、 CD8T细胞凋亡的影响[J].第三军大学学报,2000,22(2)：139-149.
[88]徐艳,万屏,何黎,等.昆明山海棠片对小鼠淋巴细胞体外增殖活化影响的研究[J].中药材,2008,31(4)：557-561.
[89]李晟,徐开林,李振宇,等.昆明山海棠提取物对异基因骨髓移植小鼠调节性T细胞的影响[J].中国中西医结合杂志,2009,29(10)：910-914.
[90]周江桥,陈晖,陈志远,等.雷公藤内酯醇对大鼠肾缺血再灌注损伤时Toll样受体4表达的影响[J].中华器官移植杂志,2010,31(11)：688-693.
[91]黄晓春,周燕虹,杨录军,等.昆明山海棠总生物碱体外抗肿瘤作用的研究[J].中国医药学杂志,2006,26(4)：442-445.
[92]白玲,陈森洲,梁爽,等.昆明山海棠对CIA大鼠模型中HIF-1α表达的影响[J].细胞与分子免疫学杂志,2011,27(10)：1061-1064
[93]刘剑毅,罗先饮,黄思行.昆明山海棠片对大鼠睾丸功能标志酶活性的影响[C].首届中国药物毒理学年会,上海,2011.
[94]徐成康,赵云荷.昆明山海棠对育龄期妇女卵巢功能的影响[J].中山大学学报(医学科学版),2008,29(2)：202-205.
[95]钟美英,申玉华.川续断的研究现状[J].中医药导报,2008,14(6)：137-139.
[96]高秀芝,马鲁豫,金艳霞,等.川续断化学成分及药理作用研究进展[J].亚太传统医药学,2010,6(7)：142-146.
[97]刘二伟,吴帅,樊官伟.川续断的化学成分及药理作用进展[J].中华中医药学刊,2010,28(7)：1421-1423.
[98]张琪,汪仙阳,马博,等.复方续断总皂苷镇痛抗炎及预防骨质疏松症的实验研究[J].时珍国医药,2010,21(7)：1683-1684.
[99]刘浩,刘清平,陈纪藩,等.通痹合剂2号对胶原诱导型关节炎大鼠外周血CD28和CD152表 达以及肿瘤坏死因子-α含量的影响[J].中西医结合报,2008,6(7)：744-747.
[100]肖培根.新编中药志[M].北京：化学工业出版社,2002,3：269-270.
[101]刘圣君,任君旭,刘艳凯.益母草对失血性休克大鼠血流动力学的影响[J].中国临床康复,2006,23(10)：70.
[102]刘艳凯,魏会平,杜舒婷,等.益母草注射液对失血性休克大鼠转归时淋巴循环的干预作用[J].中国微循环,2006,10(5)：349.
[104]刘建平.随机对照的依从性和意向性治疗分析[J].中国中西医结合杂志,2003,23(12)：884-886.
[104]Moreland LW. Potential biologic agents for treating rheumatoid arthritis[J]. Rheumatic Diseases Clinics of North Anlerica,2001,27:445-491.
[105]曾润铭,杜世新,吴杰,等.昆明山海棠与类风湿关节炎滑膜细胞体外增殖和凋亡[J].中国组织工程研究与临床康复,2009,13(50)：9892-9896.
[106]王建竹,连金饶,孔祥英,等.雷公藤甲素对TNF-a诱导的滑膜细胞增殖的影响及对Ras-MAPKs信号转导通路的调控作用[J].中国中医药杂志,2010,35(7)：888-891.
[107]周江桥,陈晖,陈志远,等.雷公藤内酯醇对大鼠肾缺血再灌注损伤时Toll样受体4表达的影响[J].中华器官移植杂志,2010,31(11)：688-691.
[108]吴帅,刘虹,刘二伟,等.川续断属植物化学成分的研究概况[J].中华中医药学刊,2009,27(12)：2504-2507.
[109]冀红,侯晓明,廖磊.复方益母草膏药效学实验研究[J].首都医药,2006,8(4)：41-43.
[110]黄建林,巫世瑶,古洁若,等.来氟米特治疗类风湿关节炎的上市后安全性再观察[J].广东医学,2010,31(14)：1870-1872.
[111]王艳娇,李琳芸,彭长华,等.类风湿关节炎患者血清炎性因子、ANCA水平与血管内皮损伤标志物的相关性分析[J].循环学杂志,2012,22(1)：49-51.
[112]王宏伟,类风湿关节炎患者血清肿瘤坏死因子α的水平测定与临床意义[J].甘肃中医学院学报,2011,(28)6：51-52.
[113]李振彬,杨志霞,徐铮,等.活动期类风湿关节炎患者血清MMF,TNF-α,IL-1β表达的相关性研究[J].中国临床医学,2008,(15)4：558-561.
[114]Zvaifler NJ, Tsai V, Alsalamch S, et al. Pannocytes:distinetive cells found in rheumatoid arthritis articular cartilage erosions[J]. Am J Pathol 1997:150(3):1125-1138.
[115]Goto M, Sasano M, Yamanaka H, et al Spontaneous production of an interleukin IL-1 like factor by cloned Rheumatoid synovial cell in long-term culture[J]. Clin Invest,1987, 80 (3):786-796.
[116]Grabaek PM. Ultrastructural evidence for two distinct types of synoviocytes in rat synovial membrane [J]. J Ultrastruct Res, 1982, 78(3):321-339
[117]姚琦,袁丁.类风湿关节炎滑膜细胞凋亡研究进展[J].陕西医学杂志,2006(35)7：862-864.
[118]孟列素,朱文华,吕社民.Toll样受体与类风湿关节炎[J].中华风湿病学杂志,2008,1(1)：45-48.
[119]Lories RJ, Derease I, De Bari C, et al. In vitro growth rate of fibroblast-like synovial cells is reduced by methotrexate treated. Ann Rheum Dis 2003:62(6):568-71.
[120]刘巧红,沈凌汛,滕云,等.甲氨蝶呤对类风湿关节炎滑膜细胞增生及细胞周期的影响[J].中华风湿病学杂志,2004,8(4)：223-226
[121]杨志霞,李振彬,罗秋华,等雷公藤甲索含药血清对大鼠成纤维样滑膜细胞增殖及其巨噬细胞移动抑制因子表达的影响[J].中国组织工程研究与临床康复.2007,(11)49：9882-9885.
[122]叶永安,朱陵群.中药复方血清药理学方法在中医药研究中应用的思考[J].中国中医基础医学杂志,2001,(7)5：323-324.
[123]赵保胜,李兰芳,马悦颖,等.参苏饮含药血清对小鼠巨噬细胞Toll样受体及其下游信号转导通路的影响[J].中国中药杂志,2007,32(4)：327-331.
[124]LiLiu, Yu H. Li, Yin, B. Niu, et al. An apple oligogalactan prevents against inflammation and carcinogenesis by targeting LPS/TLR4/NF-KB pathway in a mouse model of colitis-associated colon cancer. [J]Carcinogenesis.2010, (31)10:1822-1832.
[125]朱熠,黄建鸣,张国楠TLR4/MyD88信号通路介导的卵巢癌紫杉醇耐药机制的研究进展[J].中华妇产科杂志,2011,46(11)：873-875.
[126]张红鸭,康娟,韩文娟,等TLR4、 MyD88、 NF-KB mRNA在实验性自身免疫性肌炎小鼠淋巴结中的表达和意义[J].细胞与分子免疫学杂志,2012,28(3)：272-276.
[127]熊小泉,石文,黄宪章.TLR4介导的固有免疫在类风湿关节炎模型大鼠中的发病过程中的意义[J].广东医学,2009,30(10)：1471-1473.
[128]Leah Emma. Rheumatoid arthritis:Spontaneous release of cytokines from synovial tissue is blocked by anti-TLR2[J].Nature Reviews Rheumatology.2011, (7)5:254.
[129]Jin Juan, Chan Yan, Wei Wei, Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis[J]. Acta Pharmacologica Sinica.2010, (31)9:1133-1140.